Annovis Bio (ANVS) Net Cash Flow (2019 - 2026)
Annovis Bio (ANVS) posted Net Cash Flow of -$5.3 million for Q1 2026, down 225.14% sequentially from $4.2 million in Q4 2025, and down 145.47% YoY from $11.7 million in Q1 2025.
Annovis Bio (ANVS) Net Cash Flow (2019 - 2026) Analysis & Trends
Annovis Bio has reported Net Cash Flow for 8 years, with the latest figure at -$5.3 million in Q1 2026.
- Quarterly Net Cash Flow fell 145.47% year-over-year to -$5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.0 million (down 141.98% YoY) and the FY2025 annual result came in at $9.0 million, up 87.2% from the prior year.
- Net Cash Flow declined to -$5.3 million in Q1 2026 per ANVS's latest filing, from $4.2 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $11.7 million in Q1 2025 and troughed at -$11.6 million in Q1 2023.
- A 5-year average of -$1.9 million and a median of -$2.6 million in 2024 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 546.35% in 2025, down 693.16% in 2025.
- Over 5 years, Net Cash Flow stood at -$3.6 million in 2022, then soared by 83.37% to -$600222.0 in 2023, then plunged by 247.32% to -$2.1 million in 2024, then jumped by 303.67% to $4.2 million in 2025, then tumbled by 225.14% to -$5.3 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$5.3 million, $4.2 million, and -$1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Annovis Bio | 66.78 Mn | 66.78 Mn | - | 4.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.31 Mn |
| Mar 31, 2026 | -5.31 Mn |
| Dec 31, 2025 | 4.25 Mn |
| Dec 31, 2025 | 4.25 Mn |
| Sep 30, 2025 | -1.84 Mn |
| Sep 30, 2025 | -1.84 Mn |
| Jun 30, 2025 | -5.11 Mn |
| Jun 30, 2025 | -5.11 Mn |
| Mar 31, 2025 | 11.68 Mn |
| Mar 31, 2025 | 11.68 Mn |
| Dec 31, 2024 | -2.08 Mn |
| Dec 31, 2024 | -2.08 Mn |
| Sep 30, 2024 | 8.64 Mn |
| Sep 30, 2024 | 8.64 Mn |
| Jun 30, 2024 | 860,799.00 |
| Jun 30, 2024 | 860,799.00 |
| Mar 31, 2024 | -2.62 Mn |
| Mar 31, 2024 | -2.62 Mn |
| Dec 31, 2023 | -600,222.00 |
| Dec 31, 2023 | -600,222.00 |